Recent Research on Neutralizing Antibody Response to SARS-CoV-2 Variants
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Innate and Adaptive Immunity in Vaccination".
Deadline for manuscript submissions: 6 August 2025 | Viewed by 2243
Special Issue Editor
Interests: SARS-CoV-2; vaccines; natural infection; variant; immunity
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
COVID-19 continues to spread globally. Despite vaccination boosting, the risk of getting infected or reinfected with SARS-CoV-2 remains due to the emergence of viral variants. Often, these variants may evade naturally acquired or vaccine-induced immunity. Therefore, it is essential to study the relationship between genetic diversity, antibody response, and the evolution of SARS-CoV-2. The aim of this Special Issue is to evaluate recent research on the neutralizing antibody response to SARS-CoV-2 variants. We welcome original research articles and reviews. Research areas may include but are not limited to SARS-CoV-2 and vaccines, SARS-CoV-2 and natural infection, immunity mechanisms, competition between variants, vaccine escape, and SARS-CoV-2 dynamics.
We look forward to receiving your contributions.
Dr. Chloé Dimeglio
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- SARS-CoV-2 and vaccines
- SARS-CoV-2 and natural infection
- immunity mechanism
- competition between variants
- SARS-CoV-2 dynamics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
